Unaccounted for regression to the mean renders conclusion of article titled "Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin" unsubstantiated.
作者信息
Kahathuduwa Chanaka N, Thomas Diana M, Siu Cynthia, Allison David B
机构信息
Department of Human Development and Family Studies, Texas Tech University, Lubbock, Texas.
Department of Physiology, Faculty of Medicine, University of Peradeniya, Peradeniya, Sri Lanka.
出版信息
Diabetes Obes Metab. 2018 Aug;20(8):2039-2040. doi: 10.1111/dom.13323. Epub 2018 May 3.
Abstract
摘要
相似文献
1
Unaccounted for regression to the mean renders conclusion of article titled "Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin" unsubstantiated.未考虑到的均值回归使得标题为“使用钠-葡萄糖协同转运蛋白2抑制剂托格列净降低尿酸与糖化血红蛋白降低的关系”的文章结论缺乏依据。
Diabetes Obes Metab. 2018 Aug;20(8):2039-2040. doi: 10.1111/dom.13323. Epub 2018 May 3.
2
This is in reply to the Letter by Kahathuduwa et al. titled "Unaccounted for regression to the mean renders conclusion of article titled 'Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor Tofogliflozin' unsubstantiated".这是对卡哈图杜瓦等人题为《未考虑到的均值回归使得题为“使用钠-葡萄糖协同转运蛋白2抑制剂托格列净降低尿酸与糖化血红蛋白降低的关系”的文章结论缺乏依据》的信件的回复。
Diabetes Obes Metab. 2018 Aug;20(8):2041-2042. doi: 10.1111/dom.13347. Epub 2018 Jun 5.
3
Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin.与 SGLT2 抑制剂托格列净降低 HbA1c 相关的尿酸降低。
Diabetes Obes Metab. 2018 Apr;20(4):1061-1065. doi: 10.1111/dom.13170. Epub 2018 Jan 8.
4
Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.托格列净，一种新型钠-葡萄糖协同转运蛋白2抑制剂，可改善db/db小鼠的肾功能和胰腺功能。
Br J Pharmacol. 2013 Oct;170(3):519-31. doi: 10.1111/bph.12269.
5
Tofogliflozin: a highly selective SGLT2 inhibitor for the treatment of type 2 diabetes.托格列净：一种用于治疗2型糖尿病的高选择性钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂。
Drugs Today (Barc). 2014 Nov;50(11):739-45. doi: 10.1358/dot.2014.50.11.2232267.
6
Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.在胰岛素治疗下血糖控制不佳的日本 2 型糖尿病患者中托格列净的疗效和安全性（J-STEP/INS）：一项 16 周随机、双盲、安慰剂对照、多中心试验的结果。
Diabetes Obes Metab. 2017 Oct;19(10):1397-1407. doi: 10.1111/dom.12957. Epub 2017 Jul 13.
7
A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus.一种新型选择性钠-葡萄糖协同转运蛋白2抑制剂托格列净可改善2型糖尿病患者的血糖控制并降低体重。
Diabetes Obes Metab. 2015 Oct;17(10):984-93. doi: 10.1111/dom.12538. Epub 2015 Aug 20.
8
Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.托格列净，一种强效且高度特异的钠/葡萄糖共转运蛋白 2 抑制剂，可改善糖尿病大鼠和小鼠的血糖控制。
J Pharmacol Exp Ther. 2012 Jun;341(3):692-701. doi: 10.1124/jpet.112.191593. Epub 2012 Mar 12.
9
Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials.钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂对血尿酸水平的影响：一项随机对照试验的荟萃分析。
Diabetes Obes Metab. 2018 Feb;20(2):458-462. doi: 10.1111/dom.13101. Epub 2017 Sep 27.
10
Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study.新型钠-葡萄糖协同转运蛋白2抑制剂托格列净单药治疗日本2型糖尿病患者的疗效和安全性：一项2期和3期联合随机、安慰剂对照、双盲、平行组比较研究。
Cardiovasc Diabetol. 2014 Mar 28;13:65. doi: 10.1186/1475-2840-13-65.
引用本文的文献
1
Regression to the Mean: A Statistical Phenomenon of Worthy Consideration in Anemia Research.均值回归：贫血研究中值得考虑的一种统计现象。
Curr Dev Nutr. 2020 Sep 24;4(10):nzaa152. doi: 10.1093/cdn/nzaa152. eCollection 2020 Oct.
2
Best (but oft-forgotten) practices: identifying and accounting for regression to the mean in nutrition and obesity research.最佳（但常被遗忘）实践：在营养和肥胖研究中识别和考虑均值回归。
Am J Clin Nutr. 2020 Feb 1;111(2):256-265. doi: 10.1093/ajcn/nqz196.
本文引用的文献
1
Regression to the mean, apparent data errors and biologically extraordinary results: letter regarding 'changes in telomere length 3-5 years after gastric bypass surgery'.向均值回归、明显的数据误差和生物学上异常的结果：关于“胃旁路手术后3至5年端粒长度的变化”的信函
Int J Obes (Lond). 2018 Apr;42(4):949-950. doi: 10.1038/ijo.2017.298. Epub 2017 Dec 12.
2
Letter to the editor.致编辑的信。
J Women Aging. 2018 Jan-Feb;30(1):2-5. doi: 10.1080/08952841.2017.1407575.
3
Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin.与 SGLT2 抑制剂托格列净降低 HbA1c 相关的尿酸降低。
Diabetes Obes Metab. 2018 Apr;20(4):1061-1065. doi: 10.1111/dom.13170. Epub 2018 Jan 8.
4
Correction to: Effectiveness of Nutrition Intervention in a Selected Group of Overweight and Obese African-American Preschoolers.对《特定超重和肥胖非裔美国学龄前儿童营养干预的有效性》的更正
J Racial Ethn Health Disparities. 2018 Jun;5(3):562. doi: 10.1007/s40615-017-0436-z.
5
Do Obese and Extremely Obese Patients Lose Weight After Lumbar Spine Fusions? Analysis of a Cohort of 7303 Patients from the Kaiser National Spine Registry.肥胖和极肥胖患者腰椎融合术后会减重吗？来自 Kaiser 国家脊柱注册中心的 7303 例患者队列分析。
Spine (Phila Pa 1976). 2018 Jan 1;43(1):22-27. doi: 10.1097/BRS.0000000000002456.
6
Common scientific and statistical errors in obesity research.肥胖研究中常见的科学和统计错误。
Obesity (Silver Spring). 2016 Apr;24(4):781-90. doi: 10.1002/oby.21449.
7
Regression to the Mean: A Commonly Overlooked and Misunderstood Factor Leading to Unjustified Conclusions in Pediatric Obesity Research.均值回归：儿科肥胖研究中一个常被忽视和误解的因素，会导致不合理的结论。
Child Obes. 2016 Apr;12(2):155-8. doi: 10.1089/chi.2015.0222. Epub 2016 Mar 14.
8
Best (but oft forgotten) practices: testing for treatment effects in randomized trials by separate analyses of changes from baseline in each group is a misleading approach.最佳（但常常被遗忘）的做法：在随机试验中，通过对每组相对于基线的变化进行单独分析来检验治疗效果是一种误导性的方法。
Am J Clin Nutr. 2015 Nov;102(5):991-4. doi: 10.3945/ajcn.115.119768. Epub 2015 Sep 9.
9
Ignoring regression to the mean leads to unsupported conclusion about obesity.忽视均值回归会导致关于肥胖的无根据结论。
Int J Behav Nutr Phys Act. 2015 May 7;12:56. doi: 10.1186/s12966-015-0212-6.
10
Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study.新型钠-葡萄糖协同转运蛋白2抑制剂托格列净单药治疗日本2型糖尿病患者的疗效和安全性：一项2期和3期联合随机、安慰剂对照、双盲、平行组比较研究。
Cardiovasc Diabetol. 2014 Mar 28;13:65. doi: 10.1186/1475-2840-13-65.
Zotero 插件